Stock Performance and Market Context
The stock’s latest low comes amid a challenging period for Shree Ganesh Biotech India Ltd, which has seen its share price fall by 42.86% over the last 12 months. This contrasts sharply with the broader Sensex index, which has declined by only 0.67% during the same period. The stock’s 52-week high was Rs.0.99, indicating a substantial drop of 45.5% from that peak.
On the day the new low was recorded, the stock outperformed its sector by 1.47%, despite trading below all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — signalling persistent downward momentum. The Sensex itself opened sharply lower by 1,953.21 points but recovered somewhat to trade at 74,972.67, still down 2.26% and close to its own 52-week low of 71,425.01.
Financial and Operational Metrics
Shree Ganesh Biotech India Ltd’s financial indicators reflect ongoing difficulties. The company has reported operating losses, contributing to a weak long-term fundamental strength assessment. Its ability to service debt remains constrained, with an average EBIT to interest ratio of just 0.82, indicating insufficient earnings before interest and taxes to comfortably cover interest expenses.
Profitability metrics also remain subdued. The average return on equity (ROE) stands at 2.62%, signalling limited profitability generated per unit of shareholders’ funds. Additionally, the company’s debtors turnover ratio for the half-year period is at a notably low 0.00 times, suggesting challenges in collecting receivables efficiently.
Profitability and Valuation Trends
Over the past year, the company’s profits have declined by 115.5%, a steep contraction that has contributed to the stock’s negative returns. The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) remain negative, further underscoring the financial strain. Valuation metrics indicate the stock is trading at riskier levels compared to its historical averages, reflecting investor caution.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Shareholding and Market Sentiment
The majority of Shree Ganesh Biotech India Ltd’s shares are held by non-institutional investors, which may contribute to higher volatility and less stable trading patterns. The company’s Mojo Score currently stands at 12.0, with a Mojo Grade of Strong Sell, an upgrade from the previous Sell rating as of 8 August 2024. This grading reflects the company’s micro-cap status and the ongoing concerns regarding its financial health and market performance.
Technical Indicators Overview
Technical analysis presents a mixed picture. On a weekly basis, the Moving Average Convergence Divergence (MACD) indicator is bearish, while the monthly MACD shows mild bullishness. The Relative Strength Index (RSI) is neutral weekly but bullish monthly. Bollinger Bands indicate bearish trends on both weekly and monthly charts. Daily moving averages remain bearish, and the Dow Theory signals no clear weekly trend but a bearish monthly outlook. The KST indicator is mildly bullish weekly but bearish monthly, suggesting some short-term fluctuations amid longer-term weakness.
Holding Shree Ganesh Biotech India Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India Ltd’s performance has lagged behind peers and the broader market indices. The Sensex’s relative resilience compared to the stock’s steep decline highlights the company’s specific challenges rather than sector-wide issues. The stock’s current trading below all major moving averages contrasts with the sector’s more stable performance, emphasising the stock’s weaker technical position.
Summary of Key Concerns
In summary, Shree Ganesh Biotech India Ltd’s fall to Rs.0.54 marks a significant low point driven by a combination of weak profitability, negative EBITDA, poor debt servicing capacity, and subdued operational metrics such as debtor turnover. The stock’s technical indicators largely reflect bearish momentum, while the company’s micro-cap status and non-institutional shareholding pattern contribute to its volatility. Despite some mild bullish signals on monthly technicals, the overall picture remains cautious.
Market Environment
The broader market environment has been volatile, with the Sensex experiencing a gap down opening but partial recovery during the trading session. The index remains close to its own 52-week low, trading below key moving averages, which may be indicative of wider market pressures affecting micro-cap and sector-specific stocks like Shree Ganesh Biotech India Ltd.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
